ArticleApplied and environmental microbiology2015
Improved antimicrobial activities of synthetic-hybrid bacteriocins designed from enterocin E50-52 and pediocin PA-1.
Article in Applied and environmental microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 45 citations in OpenAlex.
- mRNA mediated expression of novel fusion phage tail protein with antimicrobial peptides inside macrophages for targeted clearance of intracellularEmerging microbes & infections · 2026Article
- Current Status and Future Challenges in the Use of Bacteriocins to Modulate Ruminant Gut Microbiota.Probiotics and antimicrobial proteins · 2026Review
- Understanding the Necessity of Regulatory Protein Machinery in Heterologous Expression of Class-III Type of Ocins.The protein journal · 2023Review
- Antibacterial effectiveness of multi-strain probiotics supernatants intracanal medication on Enterococcus faecalis biofilm in a tooth model.BMC oral health · 2023Article
- Effect of Polydextrose on the Growth ofMicroorganisms · 2022Article
- Isolation and Characterization of Bacteriocin-ProducingMolecules (Basel, Switzerland) · 2022Article
- A bacteriocin-based treatment option for Staphylococcus haemolyticus biofilms.Scientific reports · 2021Article
- A Bifunctional Peptide Conjugate That Controls Infections ofMolecules (Basel, Switzerland) · 2021Article
- Can Probiotics Emerge as Effective Therapeutic Agents in Apical Periodontitis? A Review.Probiotics and antimicrobial proteins · 2021Review
- Heterologous Expression of the Leuconostoc Bacteriocin Leucocin C in Probiotic Yeast Saccharomyces boulardii.Probiotics and antimicrobial proteins · 2021Article
- Antimicrobial Peptides Derived From Insects Offer a Novel Therapeutic Option to Combat Biofilm: A Review.Frontiers in microbiology · 2021Review
- Molecular insights into probiotic mechanisms of action employed against intestinal pathogenic bacteria.Gut microbes · 2020Review
- Evaluation of antibacterial activity of enterocin A-colicin E1 fusion peptide.Iranian journal of basic medical sciences · 2020Article
- Features and applications of Ent35-MccV hybrid bacteriocin: current state and perspectives.Applied microbiology and biotechnology · 2020Review
- Hybrids made from antimicrobial peptides with different mechanisms of action show enhanced membrane permeabilization.Biochimica et biophysica acta. Biomembranes · 2019Article
- Synthesis of a Peptide Derivative of MicrocinJ25 and Evaluation of Antibacterial and Biological Activities.Iranian journal of pharmaceutical research : IJPR · 2019Article
- Synthesis, antimicrobial activity and conformational analysis of the class IIa bacteriocin pediocin PA-1 and analogs thereof.Scientific reports · 2018Article
- Purification and antibacterial mechanism of fish-borne bacteriocin and its application in shrimp (Penaeus vannamei) for inhibiting Vibrio parahaemolyticus.World journal of microbiology & biotechnology · 2017Article
- Control of Biofilm Formation: Antibiotics and Beyond.Applied and environmental microbiology · 2017Review
- Biochemical Properties and Mechanism of Action of Enterocin LD3 Purified from Enterococcus hirae LD3.Probiotics and antimicrobial proteins · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two hybrid bacteriocins, enterocin E50-52/pediocin PA-1 (EP) and pediocin PA-1/enterocin E50-52 (PE), were designed by combining the N terminus of enterocin E50-52 and the C terminus of pediocin PA-1 and by combining the C terminus of pediocin PA-1 and the N terminus of enterocin E50-52, respectively. Both hybrid bacteriocins showed reduced MICs compared to those of their natural counterparts. The MICs of hybrid PE and EP were 64- and 32-fold lower, respectively, than the MIC of pediocin PA-1 and 8- and 4-fold lower, respectively, than the MIC of enterocin E50-52. In this study, the effect of hybrid as well as wild-type (WT) bacteriocins on the transmembrane electrical potential (ΔΨ) and their ability to induce the efflux of intracellular ATP were investigated. Enterocin E50-52, pediocin PA-1, and hybrid bacteriocin PE were able to dissipate ΔΨ, but EP was unable to deplete this component. Both hybrid bacteriocins caused a loss of the intracellular concentration of ATP. EP, however, caused a faster efflux than PE and enterocin E50-52. Enterocin E50-52 and hybrids PE and EP were active against the Gram-positive and Gram-negative bacteria tested, such as Micrococcus luteus, Salmonella enterica serovar Enteritidis 20E1090, and Escherichia coli O157:H7. The hybrid bacteriocins designed and described herein are antimicrobial peptides with MICs lower those of their natural counterparts. Both hybrid peptides induce the loss of intracellular ATP and are capable of inhibiting Gram-negative bacteria, and PE dissipates the electrical potential. In this study, the MIC of hybrid bacteriocin PE decreased 64-fold compared to the MIC of its natural peptide counterpart, pediocin PA-1. Inhibition of Gram-negative pathogens confers an additional advantage for the application of these peptides in therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.